EUVIMEDEUVIMED entdecken
Vergleichsstudie

Durability and mechanistic performance of aztreonam/avibactam versus aztreonam plus ceftazidime/avibactam against Stenotrophomonas maltophilia complex

Ashlan J Kunz Coyne, Rachel Gray iD, Pavani Gonnabathula, Elizabeth S May, Paul Puccio, Christine Wu

Journal of Antimicrobial Chemotherapy · 05.05.2026 · 81 (6)

DOI: 10.1093/jac/dkag177 ↗

Kurz gefasst

Vergleichsstudie in der Zeitschrift Journal of Antimicrobial Chemotherapy, online erschienen am 22.05.2026. Verfasst von Ashlan J Kunz Coyne und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacy Practice and Science, University of Kentucky College of Pharmacy, Lexington, KY, USA. Hauptthemen laut MEDLINE: Aztreonam, Ceftazidime, Azabicyclo Compounds, Stenotrophomonas maltophilia. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 45 Literaturangaben. Gefördert von: Translational Medicine Faculty Starter, PhRMA Foundation.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Stenotrophomonas maltophilia complex infections are difficult to treat because of intrinsic resistance mediated by the L1 metallo-β-lactamase and L2 serine β-lactamase. Although aztreonam/avibactam is clinically available, aztreonam combined with ceftazidime/avibactam remains an alternative, but comparative pharmacodynamic data under clinically relevant exposures are limited. We compared aztreonam/avibactam and aztreonam + ceftazidime/avibactam under prolonged human-simulated dosing.

Methods

Three clinical S. maltophilia complex isolates (17061, 17639 and 16852) were studied in 96-h hollow fibre infection models. Human-simulated aztreonam/avibactam and aztreonam + ceftazidime/avibactam regimens were administered as 3-h extended or continuous infusions at total daily aztreonam doses of 6 g or 8 g. blaL1 and blaL2 expression was quantified by RT-qPCR, and population pharmacokinetic modelling with Monte Carlo simulation (n = 1000) verified target exposures.

Results

At 6 g/day of aztreonam, neither aztreonam/avibactam nor aztreonam + ceftazidime/avibactam achieved sustained bactericidal activity; extended infusions failed to produce killing, and continuous infusion produced only transient bactericidal effects followed by regrowth. In contrast, continuous-infusion aztreonam/avibactam at 8 g/day produced rapid and durable bactericidal activity across all isolates through 96 h with stable minimum inhibitory concentrations (MICs), whereas aztreonam + ceftazidime/avibactam at the same dose achieved early killing followed by regrowth. Transcriptionally, aztreonam/avibactam limited or uncoupled blaL1 and blaL2 induction even at intensified dosing, while aztreonam + ceftazidime/avibactam more consistently promoted blaL1 up-regulation and greater β-lactamase variability.

Conclusions

Under human-simulated conditions, only continuous-infusion aztreonam/avibactam with intensified aztreonam exposure (8 g/day) achieved durable bactericidal activity against S. maltophilia complex, whereas adding ceftazidime did not improve pharmacodynamic outcomes and was associated with greater β-lactamase induction.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

AztreonamCeftazidimeAzabicyclo CompoundsStenotrophomonas maltophiliaAnti-Bacterial AgentsHumansMicrobial Sensitivity TestsDrug Combinationsbeta-Lactamases

Substanzen

AztreonamCeftazidimeAzabicyclo CompoundsAnti-Bacterial Agentsavibactamavibactam, ceftazidime drug combinationDrug Combinationsbeta-Lactamases

Autor:innen und Institutionen

  • Department of Pharmacy Practice and Science, University of Kentucky College of Pharmacy, Lexington, KY, USA.
  • Department of Pharmacy, University of Kentucky HealthCare, Lexington, KY, USA.

ORCID-Profile: Rachel Gray

Förderung

  • Translational Medicine Faculty Starter
  • PhRMA Foundation

Zitieren

APA

Kunz Coyne, A. J., Gray, R., Gonnabathula, P., May, E. S., Puccio, P., & Wu, C. (2026). Durability and mechanistic performance of aztreonam/avibactam versus aztreonam plus ceftazidime/avibactam against Stenotrophomonas maltophilia complex. Journal of Antimicrobial Chemotherapy, 81(6). https://doi.org/10.1093/jac/dkag177

Vancouver

Kunz Coyne AJ, Gray R, Gonnabathula P, May ES, Puccio P, Wu C. Durability and mechanistic performance of aztreonam/avibactam versus aztreonam plus ceftazidime/avibactam against Stenotrophomonas maltophilia complex. Journal of Antimicrobial Chemotherapy. 2026;81(6). doi:10.1093/jac/dkag177

BibTeX
@article{KunzCoyne2026,
  author = {Kunz Coyne, Ashlan J and Gray, Rachel and Gonnabathula, Pavani and May, Elizabeth S and Puccio, Paul and Wu, Christine},
  title = {Durability and mechanistic performance of aztreonam/avibactam versus aztreonam plus ceftazidime/avibactam against Stenotrophomonas maltophilia complex},
  journal = {Journal of Antimicrobial Chemotherapy},
  year = {2026},
  volume = {81},
  number = {6},
  doi = {10.1093/jac/dkag177}
}
Kostenlos starten →